(BTI) British American Tobacco - Overview
Sector: Consumer Defensive | Industry: Tobacco | Exchange: NYSE (USA) | Market Cap: 144.277m USD | Total Return: 55.7% in 12m
Cigarettes, Vapour Products, Nicotine Pouches, Heated Tobacco, Snuff
Total Rating 65
Safety 70
Buy Signal -0.29
Tobacco
Industry Rotation: +36.6
Industry Rotation: +36.6
Market Cap:
144B
Avg Turnover: 217M
Avg Turnover: 217M
Risk 3d forecast
Volatility21.8%
VaR 5th Pctl3.75%
VaR vs Median4.36%
Reward TTM
Sharpe Ratio1.91
Rel. Str. IBD72.4
Rel. Str. Peer Group85.3
Character TTM
Beta-0.098
Beta Downside-0.292
Hurst Exponent0.466
Drawdowns 3y
Max DD13.77%
CAGR/Max DD2.54
CAGR/Mean DD7.51
EPS (Earnings per Share)
EPS CAGR: -54.01%
EPS Trend: -26.3%
EPS Trend: -26.3%
Last SUE: 0.00
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 34.37%
Rev. Trend: 97.1%
Rev. Trend: 97.1%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Description: BTI British American Tobacco
British American Tobacco p.l.c. (BTI) is a global consumer goods company specializing in the manufacture and distribution of tobacco and nicotine products. Its portfolio includes traditional combustible cigarettes, fine-cut tobacco, and New Category segments such as vapor, heated tobacco, and modern oral nicotine pouches. The company operates an extensive distribution network reaching retail outlets across six continents.
The tobacco industry is currently characterized by a structural shift as major players transition from legacy combustibles to reduced-risk alternatives to offset declining cigarette volumes in developed markets. BTI utilizes a multi-category business model, leveraging established global brands like Dunhill, Lucky Strike, and Vuse to maintain market share across different consumer price points and regulatory environments.
For a deeper look into the companys financial health and valuation metrics, consider exploring the data available on ValueRay. British American Tobacco remains headquartered in London and has maintained its operations since 1902.
- Accelerated transition to non-combustible products offsets declining traditional cigarette volumes
- FDA regulatory scrutiny of vapor and menthol products impacts US revenue
- High dividend yield and share buybacks drive total shareholder returns
- Significant debt reduction targets influence credit ratings and capital allocation
- Emerging market volume growth compensates for developed market regulatory pressures
Piotroski VR‑10 (Strict)
6.5
| Net Income: 10.83b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 1.12 > 1.0 |
| NWC/Revenue: -3.57% < 20% (prev -5.30%; Δ 1.73% < -1%) |
| CFO/TA 0.11 > 3% & CFO 12.38b > Net Income 10.83b |
| Net Debt (31.24b) to EBITDA (20.34b): 1.54 < 3 |
| Current Ratio: 0.87 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (2.20b) vs prev -1.17% < -2% |
| Gross Margin: 83.17% > 18% (prev 0.82%; Δ 8.24k% > 0.5%) |
| Asset Turnover: 45.03% > 50% (prev 34.28%; Δ 10.74% > 0%) |
| Interest Coverage Ratio: 4.64 > 6 (EBITDA TTM 20.34b / Interest Expense TTM 3.27b) |
Altman Z''
1.83
| A: -0.02 (Total Current Assets 12.68b - Total Current Liabilities 14.52b) / Total Assets 109.29b |
| B: 0.21 (Retained Earnings 22.93b / Total Assets 109.29b) |
| C: 0.13 (EBIT TTM 15.16b / Avg Total Assets 114.33b) |
| D: 0.35 (Book Value of Equity 21.25b / Total Liabilities 61.15b) |
| Altman-Z'' Score: 1.83 = BBB |
Beneish M
-3.00
| DSRI: 0.83 (Receivables 3.80b/3.64b, Revenue 51.48b/40.92b) |
| GMI: 0.99 (GM 83.17% / 82.07%) |
| AQI: 1.02 (AQ_t 0.84 / AQ_t-1 0.83) |
| SGI: 1.26 (Revenue 51.48b / 40.92b) |
| TATA: -0.01 (NI 10.83b - CFO 12.38b) / TA 109.29b) |
| Beneish M-Score: -3.00 (Cap -4..+1) = A |
What is the price of BTI shares?
As of May 21, 2026, the stock is trading at USD 65.30 with a total of 4,032,765 shares traded.
Over the past week, the price has changed by -0.08%, over one month by +14.44%, over three months by +6.72% and over the past year by +55.68%.
Over the past week, the price has changed by -0.08%, over one month by +14.44%, over three months by +6.72% and over the past year by +55.68%.
Is BTI a buy, sell or hold?
British American Tobacco has received a consensus analysts rating of 3.40.
Therefor, it is recommend to hold BTI.
- StrongBuy: 1
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the BTI price?
| Analysts Target Price | 67.2 | 3% |
British American Tobacco (BTI) - Fundamental Data Overview
as of 16 May 2026
Market Cap GBP = 107.36b (144.28b USD * 0.7441 USD.GBP)P/E Trailing = 14.1314
P/E Forward = 11.7786
P/S = 5.6336
P/B = 1.9358
P/EG = 1.4856
Revenue TTM = 51.48b GBP
EBIT TTM = 15.16b GBP
EBITDA TTM = 20.34b GBP
Long Term Debt = 31.33b GBP (from longTermDebt, last quarter)
Short Term Debt = 3.36b GBP (from shortTermDebt, last quarter)
Debt = 35.07b GBP (from shortLongTermDebtTotal, last quarter)
Net Debt = 31.24b GBP (from netDebt column, last quarter)
Enterprise Value = 138.58b GBP (107.36b + Debt 35.07b - CCE 3.84b)
Interest Coverage Ratio = 4.64 (Ebit TTM 15.16b / Interest Expense TTM 3.27b)
EV/FCF = 9.05x (Enterprise Value 138.58b / FCF TTM 15.31b)
FCF Yield = 11.05% (FCF TTM 15.31b / Enterprise Value 138.58b)
FCF Margin = 29.74% (FCF TTM 15.31b / Revenue TTM 51.48b)
Net Margin = 21.04% (Net Income TTM 10.83b / Revenue TTM 51.48b)
Gross Margin = 83.17% ((Revenue TTM 51.48b - Cost of Revenue TTM 8.66b) / Revenue TTM)
Gross Margin QoQ = 83.42% (prev 83.59%)
Tobins Q-Ratio = 1.27 (Enterprise Value 138.58b / Total Assets 109.29b)
Interest Expense / Debt = 2.18% (Interest Expense 764.0m / Debt 35.07b)
Taxrate = 25.32% (1.08b / 4.29b)
NOPAT = 11.32b (EBIT 15.16b * (1 - 25.32%))
Current Ratio = 0.87 (Total Current Assets 12.68b / Total Current Liabilities 14.52b)
Debt / Equity = 0.73 (Debt 35.07b / totalStockholderEquity, last quarter 47.93b)
Debt / EBITDA = 1.54 (Net Debt 31.24b / EBITDA 20.34b)
Debt / FCF = 2.04 (Net Debt 31.24b / FCF TTM 15.31b)
Total Stockholder Equity = 49.64b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.47% (Net Income 10.83b / Total Assets 109.29b)
RoE = 21.82% (Net Income TTM 10.83b / Total Stockholder Equity 49.64b)
RoCE = 18.72% (EBIT 15.16b / Capital Employed (Equity 49.64b + L.T.Debt 31.33b))
RoIC = 19.42% (NOPAT 11.32b / Invested Capital 58.27b)
WACC = 4.65% (E(107.36b)/V(142.43b) * Re(5.64%) + D(35.07b)/V(142.43b) * Rd(2.18%) * (1-Tc(0.25)))
Discount Rate = 5.64% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: -79.57 | Cagr: -1.35%
[DCF] Terminal Value 87.46% ; FCFF base≈15.34b ; Y1≈17.31b ; Y5≈23.39b
[DCF] Fair Price = 302.8 (EV 686.21b - Net Debt 31.24b = Equity 654.97b / Shares 2.16b; r=6.0% [WACC]; 5y FCF grow 14.95% → 3.0% )
EPS Correlation: -26.32 | EPS CAGR: -54.01% | SUE: 0.0 | # QB: 0
Revenue Correlation: 97.05 | Revenue CAGR: 34.37% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=4.90 | Chg30d=+0.22% | Revisions=N/A | GrowthEPS=+2.0% | GrowthRev=+2.8%
EPS next Year (2027-12-31): EPS=5.32 | Chg30d=+0.53% | Revisions=-20% | GrowthEPS=+8.6% | GrowthRev=+3.3%
[Analyst] Revisions Ratio: -20%